About SeqOnce BioSciences
SeqOnce BioSciences is a private company based in Pasadena, California. It has reported $1,892,740 raised in two offerings on Form D since April 2018. Its chief executive is Christopher Angermayer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | Nov 5, 2024 | $881,831fully sold | 4 | $220K | Equity, OptionsRule 506(b) | Form D ↗ |
| Apr 20, 2018 | Apr 27, 2018 | $1,010,909of $1.2M target | 12 | $84,242 | Equity, OptionsRule 506(b) | Form D ↗ |
| Total, two offerings | $1,892,740 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on SeqOnce BioSciences's Form D filed Nov 5, 2024.
CA
Christopher Angermayer
Chief Executive Officer and director
JD
Joseph Dunham
Director
Earlier filings also listed Michael Giardello (director, last listed Apr 2018).